Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

They are so effective, in one trial, patients who took the highest dose of Wegovy, which is only prescribed for weight loss, ...

25 2024. (AP Photo/Manuel Balce Ceneta) WASHINGTON — Millions of Americans with obesity would be eligible to have popular ...

Ozempic and Wegovy, used for diabetes and weight loss, show a link to NAION, a rare eye disorder causing blindness. A study ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.